{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T07:59:05Z","timestamp":1694159945100},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,2,22]],"date-time":"2018-02-22T00:00:00Z","timestamp":1519257600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s00105-018-4131-8","type":"journal-article","created":{"date-parts":[[2018,2,22]],"date-time":"2018-02-22T08:04:20Z","timestamp":1519286660000},"page":"217-224","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Neues in der Systemtherapie der atopischen Dermatitis"],"prefix":"10.1007","volume":"69","author":[{"given":"T.","family":"Werfel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Wollenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Pumnea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Heratizadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,22]]},"reference":[{"key":"4131_CR1","doi-asserted-by":"publisher","first-page":"368","DOI":"10.5021\/ad.2013.25.3.368","volume":"25","author":"A Agusti-Mejias","year":"2013","unstructured":"Agusti-Mejias A, Messeguer F, Garcia R et al (2013) Severe refractory atopic dermatitis in an adolescent patient successfully treated with ustekinumab. Ann Dermatol 25:368\u2013370","journal-title":"Ann Dermatol"},{"key":"4131_CR2","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jaip.2012.09.002","volume":"1","author":"PD Arkwright","year":"2013","unstructured":"Arkwright PD, Motala C, Subramanian H et al (2013) Management of difficult-to-treat atopic dermatitis. J\u00a0Allergy Clin Immunol Pract 1:142\u2013151","journal-title":"J Allergy Clin Immunol Pract"},{"key":"4131_CR3","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, De Bruin-Weller M, Gooderham M et al (2017) Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a\u00a01-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 389:2287\u20132303","journal-title":"Lancet"},{"key":"4131_CR4","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/S2213-2600(15)00197-6","volume":"3","author":"CE Brightling","year":"2015","unstructured":"Brightling CE, Chanez P, Leigh R et al (2015) Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a\u00a0randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med 3:692\u2013701","journal-title":"Lancet Respir Med"},{"key":"4131_CR5","volume-title":"Schwerwiegendes Risiko f\u00fcr Teratogenit\u00e4t \u2013 wichtige neue Hinweise zur Schwangerschaftsverh\u00fctung f\u00fcr Frauen und M\u00e4nner","author":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte. Mycophenolatmofetil (CellCept\u00ae)","year":"2015","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte. Mycophenolatmofetil (CellCept\u00ae) (2015) Schwerwiegendes Risiko f\u00fcr Teratogenit\u00e4t \u2013 wichtige neue Hinweise zur Schwangerschaftsverh\u00fctung f\u00fcr Frauen und M\u00e4nner. \n                    https:\/\/www.bfarm.de\/SharedDocs\/Downloads\/DE\/Arzneimittel\/Pharmakovigilanz\/Risikoinformationen\/RI_rhb\/2015\/rhb-cellcept.pdf?__blob=publicationFile&v=2\n                    \n                   (Erstellt: 10. Nov. 2015). Zugegriffen: 16.01.2018"},{"key":"4131_CR6","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.cell.2017.06.046","volume":"170","author":"HY Chang","year":"2017","unstructured":"Chang HY, Nadeau KC (2017) IL-4Ralpha inhibitor for atopic disease. Cell 170:222","journal-title":"Cell"},{"key":"4131_CR7","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.jaci.2011.10.042","volume":"129","author":"C Cornelissen","year":"2012","unstructured":"Cornelissen C, Marquardt Y, Czaja K et al (2012) IL-31 regulates differentiation and filaggrin expression in human organotypic skin models. J\u00a0Allergy Clin Immunol 129:426\u2013433.e1-8","journal-title":"J Allergy Clin Immunol"},{"key":"4131_CR8","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1111\/bjd.13730","volume":"172","author":"J Der Schaft Van","year":"2015","unstructured":"Van Der Schaft J, Politiek K, Van Den Reek JM et al (2015) Drug survival for ciclosporin A in a\u00a0long-term daily practice cohort of adult patients with atopic dermatitis. Br J Dermatol 172:1621\u20131627","journal-title":"Br J Dermatol"},{"key":"4131_CR9","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/pde.13209","volume":"34","author":"V Dvorakova","year":"2017","unstructured":"Dvorakova V, O\u2019regan GM, Irvine AD (2017) Methotrexate for severe childhood atopic dermatitis: clinical experience in a\u00a0tertiary center. Pediatr Dermatol 34:528\u2013534","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"4131_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/all.13239","volume":"73","author":"M Furue","year":"2018","unstructured":"Furue M, Yamamura K, Kido-Nakahara M et al (2018) Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis. Allergy 73(1):29\u201336. \n                    https:\/\/doi.org\/10.1111\/all.13239","journal-title":"Allergy"},{"key":"4131_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16240","author":"LAA Gerbens","year":"2017","unstructured":"Gerbens LAA, Hamann Sa Brouwer SAS, Brouwer MWD et al (2017) Methotrexate and azathioprine in severe atopic dermatitis: a\u00a05-year follow up study of a\u00a0randomised controlled trial. Br J Dermatol. \n                    https:\/\/doi.org\/10.1111\/bjd.16240","journal-title":"Br J Dermatol"},{"key":"4131_CR12","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/j.1365-2133.2009.09522.x","volume":"162","author":"M Grahovac","year":"2010","unstructured":"Grahovac M, Molin S, Prinz JC et\u00a0al (2010) Treatment of atopic eczema with oral alitretinoin. Br J Dermatol 162:217\u2013218","journal-title":"Br J Dermatol"},{"issue":"86","key":"4131_CR13","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.jaci.2017.04.015","volume":"140","author":"Y Han","year":"2017","unstructured":"Han Y, Chen Y, Liu X et al (2017) Efficacy and safety of dupilumab for the treatment of adult atopic dermatitis: a meta-analysis of randomized clinical trials. J\u00a0Allergy Clin Immunol 140(86):888\u2013891.e8","journal-title":"J Allergy Clin Immunol"},{"key":"4131_CR14","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1111\/all.13065","volume":"71","author":"A Heratizadeh","year":"2016","unstructured":"Heratizadeh A, Werfel T (2016) Anti-inflammatory therapies in atopic dermatitis. Allergy 71:1666\u20131675","journal-title":"Allergy"},{"key":"4131_CR15","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.jaci.2017.01.029","volume":"140","author":"A Heratizadeh","year":"2017","unstructured":"Heratizadeh A, Werfel T, Wollenberg A et\u00a0al (2017) Effects of structured patient education in adults with atopic dermatitis: multicenter randomized controlled trial. J\u00a0Allergy Clin Immunol 140:845\u2013853","journal-title":"J Allergy Clin Immunol"},{"key":"4131_CR16","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/exd.13112","volume":"26","author":"S Khattri","year":"2017","unstructured":"Khattri S, Brunner PM, Garcet S et al (2017) Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis. Exp Dermatol 26:28\u201335","journal-title":"Exp Dermatol"},{"key":"4131_CR17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/1346-8138.12726","volume":"42","author":"Y Murata","year":"2015","unstructured":"Murata Y, Song M, Kikuchi H et al (2015) Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a\u00a0H4 R\u2011antagonist (JNJ-39758979) in Japanese adults with moderate atopic dermatitis. J\u00a0Dermatol 42:129\u2013139","journal-title":"J Dermatol"},{"key":"4131_CR18","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/bjd.14207","volume":"174","author":"O Nemoto","year":"2016","unstructured":"Nemoto O, Furue M, Nakagawa H et al (2016) The first trial of CIM331, a\u00a0humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a\u00a0single dose in a\u00a0randomized, double-blind, placebo-controlled study. Br J Dermatol 174:296\u2013304","journal-title":"Br J Dermatol"},{"key":"4131_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15262","author":"E Nic Dhonncha","year":"2016","unstructured":"Nic Dhonncha E, Clowry J, Dunphy M et\u00a0al (2016) Treatment of severe atopic dermatitis with ustekinumab: a\u00a0case series of 10 patients. Br J Dermatol. \n                    https:\/\/doi.org\/10.1111\/bjd.15262","journal-title":"Br J Dermatol"},{"key":"4131_CR20","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.jaci.2017.07.006","volume":"140","author":"AS Paller","year":"2017","unstructured":"Paller AS, Kabashima K, Bieber T (2017) Therapeutic pipeline for atopic dermatitis: end of the drought? J\u00a0Allergy Clin Immunol 140:633\u2013643","journal-title":"J Allergy Clin Immunol"},{"key":"4131_CR21","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/j.1365-4632.2011.05195.x","volume":"51","author":"R Puya","year":"2012","unstructured":"Puya R, Alvarez-Lopez M, Velez A et al (2012) Treatment of severe refractory adult atopic dermatitis with ustekinumab. Int J Dermatol 51:115\u2013116","journal-title":"Int J Dermatol"},{"key":"4131_CR22","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1111\/j.1468-3083.2012.04635.x","volume":"26","author":"J Ring","year":"2012","unstructured":"Ring J, Alomar A, Bieber T et\u00a0al (2012) Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J\u00a0Eur Acad Dermatol Venereol 26:1045\u20131060","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4131_CR23","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/j.1468-3083.2012.04636.x","volume":"26","author":"J Ring","year":"2012","unstructured":"Ring J, Alomar A, Bieber T et\u00a0al (2012) Guidelines for treatment of atopic eczema (atopic dermatitis) part II. J\u00a0Eur Acad Dermatol Venereol 26:1176\u20131193","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4131_CR24","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/all.12779","volume":"71","author":"K Rossbach","year":"2016","unstructured":"Rossbach K, Schaper K, Kloth C et\u00a0al (2016) Histamine H4 receptor knockout mice display reduced inflammation in a\u00a0chronic model of atopic dermatitis. Allergy 71:189\u2013197","journal-title":"Allergy"},{"key":"4131_CR25","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1056\/NEJMoa1606490","volume":"376","author":"T Ruzicka","year":"2017","unstructured":"Ruzicka T, Hanifin JM, Furue M et al (2017) Anti-Interleukin-31 receptor A antibody for atopic dermatitis. N\u00a0Engl J Med 376:826\u2013835","journal-title":"N Engl J Med"},{"key":"4131_CR26","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/bjd.15493","volume":"177","author":"H Saeki","year":"2017","unstructured":"Saeki H, Kabashima K, Tokura Y et al (2017) Efficacy and safety of ustekinumab in Japanese patients with severe atopic dermatitis: a\u00a0randomized, double-blind, placebo-controlled, phase II study. Br J Dermatol 177:419\u2013427","journal-title":"Br J Dermatol"},{"key":"4131_CR27","volume-title":"Fachinformation: Dupixent 300\u202fmg Injektionsl\u00f6sung in einer Fertigspritze. Stand der Information: September 2017","author":"Sanofi Genzyme","year":"2017","unstructured":"Sanofi Genzyme (2017) Fachinformation: Dupixent 300\u202fmg Injektionsl\u00f6sung in einer Fertigspritze. Stand der Information: September 2017"},{"key":"4131_CR28","first-page":"49","volume":"15","author":"J Schmitt","year":"2017","unstructured":"Schmitt J, Abraham S, Trautmann F et al (2017) Einsatz und Wirksamkeit von Systemtherapien bei Erwachsenen mit schwerer Neurodermitis: Erste Ergebnisse des deutschen Neurodermitis-Registers TREATgermany. J\u00a0Dtsch Dermatol Ges 15:49\u201360","journal-title":"J Dtsch Dermatol Ges"},{"key":"4131_CR29","first-page":"1822","volume":"109","author":"HW Seyberth","year":"2012","unstructured":"Seyberth HW (2012) P\u00e4diatrie: Rezeptfreie Antihistaminika bergen Risiken f\u00fcr Kleinkinder. Dtsch Arztebl Int 109:1822\u20131823","journal-title":"Dtsch Arztebl Int"},{"key":"4131_CR30","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/all.12351","volume":"69","author":"D Simon","year":"2014","unstructured":"Simon D, Aeberhard C, Erdemoglu Y et\u00a0al (2014) Th17 cells and tissue remodeling in atopic and contact dermatitis. Allergy 69:125\u2013131","journal-title":"Allergy"},{"key":"4131_CR31","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E et al (2016) Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N\u00a0Engl J Med 375:2335\u20132348","journal-title":"N Engl J Med"},{"key":"4131_CR32","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.jaad.2017.06.042","volume":"77","author":"EL Simpson","year":"2017","unstructured":"Simpson EL, Bruin-Weller M, Flohr C et al (2017) When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. J\u00a0Am Acad Dermatol 77:623\u2013633","journal-title":"J Am Acad Dermatol"},{"key":"4131_CR33","doi-asserted-by":"publisher","first-page":"503","DOI":"10.5021\/ad.2017.29.4.503","volume":"29","author":"JH Son","year":"2017","unstructured":"Son JH, Park SY, Cho YS et\u00a0al (2017) Two cases of successful treatment of refractory chronic inflammatory skin disease, atopic dermatitis and psoriasis with oral alitretinoin. Ann Dermatol 29:503\u2013506","journal-title":"Ann Dermatol"},{"key":"4131_CR34","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jaci.2013.04.046","volume":"132","author":"M Suarez-Farinas","year":"2013","unstructured":"Suarez-Farinas M, Dhingra N, Gittler J et al (2013) Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. J\u00a0Allergy Clin Immunol 132:361\u2013370","journal-title":"J Allergy Clin Immunol"},{"key":"4131_CR35","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1080\/09546634.2016.1227420","volume":"28","author":"JL Thijs","year":"2017","unstructured":"Thijs JL, Van Der Geest BAM, Van Der Schaft J et\u00a0al (2017) Predicting therapy response to mycophenolic acid using UGT1A9 genotyping: towards personalized medicine in atopic dermatitis. J\u00a0Dermatolog Treat 28:242\u2013245","journal-title":"J Dermatolog Treat"},{"key":"4131_CR36","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15905","author":"A Tsianakas","year":"2017","unstructured":"Tsianakas A, Luger TA, Radin A (2017) Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a\u00a0randomized, placebo-controlled clinical trial. Br J Dermatol. \n                    https:\/\/doi.org\/10.1111\/bjd.15905","journal-title":"Br J Dermatol"},{"issue":"3","key":"4131_CR37","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jaad.2016.07.047","volume":"76","author":"D Weiss","year":"2017","unstructured":"Weiss D, Schaschinger M, Ristl R et al (2017) Ustekinumab treatment in severe atopic dermatitis: down-regulation of T\u2011helper 2\/22 expression. J\u00a0Am Acad Dermatol 76(3):91\u201397.e9","journal-title":"J Am Acad Dermatol"},{"key":"4131_CR38","first-page":"e1","volume":"14","author":"T Werfel","year":"2016","unstructured":"Werfel T, Aberer W, Ahrens F et\u00a0al (2016) Leitlinie Neurodermitis [atopisches Ekzem; atopische Dermatitis]. J\u00a0Dtsch Dermatol Ges 14:e1\u2013e75","journal-title":"J Dtsch Dermatol Ges"},{"key":"4131_CR39","first-page":"92","volume":"14","author":"T Werfel","year":"2016","unstructured":"Werfel T, Heratizadeh A, Aberer W et\u00a0al (2016) S2k guideline on diagnosis and treatment of atopic dermatitis\u2014short version. J\u00a0Dtsch Dermatol Ges 14:92\u2013106","journal-title":"J Dtsch Dermatol Ges"},{"key":"4131_CR40","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/all.12971","volume":"71","author":"T Werfel","year":"2016","unstructured":"Werfel T, Lynch V, Asher A et al (2016) A phase 2a proof of concept clinical trial to evaluate ZPL-3893787 (ZPL-389), a\u00a0potent, oral histamine H4 receptor antagonist for the treatment of moderate to severe atopic dermatitis (AD) in adults. Allergy 71:95","journal-title":"Allergy"},{"key":"4131_CR41","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/ced.12847","volume":"41","author":"C Wlodek","year":"2016","unstructured":"Wlodek C, Hewitt H, Kennedy CT (2016) Use of ustekinumab for severe refractory atopic dermatitis in a\u00a0young teenager. Clin Exp Dermatol 41:625\u2013627","journal-title":"Clin Exp Dermatol"},{"key":"4131_CR42","doi-asserted-by":"publisher","first-page":"253","DOI":"10.5021\/ad.2012.24.3.253","volume":"24","author":"A Wollenberg","year":"2012","unstructured":"Wollenberg A, Ehmann LM (2012) Long term treatment concepts and proactive therapy for atopic eczema. Ann Dermatol 24:253\u2013260","journal-title":"Ann Dermatol"},{"key":"4131_CR43","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/jdv.13599","volume":"30","author":"A Wollenberg","year":"2016","unstructured":"Wollenberg A, Oranje A, Deleuran M et\u00a0al (2016) ETFAD\/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. J\u00a0Eur Acad Dermatol Venereol 30:729\u2013747","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4131_CR44","volume-title":"A phase 2b dose-ranging efficacy and safety study of tralokinumab in adult patients with moderate to severe atopic dermatitis (AD). AAD Poster #4496","author":"A Wollenberg","year":"2017","unstructured":"Wollenberg A, Birrel C, Dawson M et al (2017) A phase 2b dose-ranging efficacy and safety study of tralokinumab in adult patients with moderate to severe atopic dermatitis (AD). AAD Poster #4496"},{"key":"4131_CR45","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s15006-017-0330-y","volume":"159","author":"A Wollenberg","year":"2017","unstructured":"Wollenberg A, Renner E, Hagl B (2017) Atopic eczema in childhood or primary immunodeficiency \u2013 what needs to be considered? MMW Fortschr Med 159:59\u201363","journal-title":"MMW Fortschr. Med."}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-018-4131-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-018-4131-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-018-4131-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T00:09:53Z","timestamp":1550794193000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-018-4131-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,22]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["4131"],"URL":"https:\/\/doi.org\/10.1007\/s00105-018-4131-8","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,22]]},"assertion":[{"value":"22 February 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"T.\u00a0Werfel gibt Interessenkonflikte f\u00fcr honorierte Vortr\u00e4ge und die Teilnahme an honorierten klinischen Studien und\/oder Beratung f\u00fcr die Firmen Galderma, Janssen, Novartis, Sanofi, Ziarco Pharma Ltd an. A.\u00a0Wollenberg gibt Interessenkonflikte f\u00fcr honorierte Vortr\u00e4ge und die Teilnahme an honorierten klinischen Studien und\/oder Beratung f\u00fcr die Firmen Anacor Pharmaceuticals, Chugai, Galderma, LEO Pharma, MedImmune, Novartis, Pfizer, Regeneron und Sanofi an. T.\u00a0Pumnea gibt an, dass kein Interessenkonflikt besteht, und A.\u00a0Heratizadeh hat Honorare f\u00fcr wissenschaftliche Vortr\u00e4ge von Novartis, Leo Pharma GmbH und Ziarco Pharma Ltd erhalten.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}